Clinical Trial Update: Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating daratumumab with bortezomib and dexamethasone in relapsed/refractory multiple myeloma with severe renal impairment has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)

Snippet

Sponsor: Universitätsklinikum Hamburg-Eppendorf | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED